Gene Therapy

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Insights from a genome-wide association study identify novel genetic loci

The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

A large-scale study indicates women are more likely to develop the inherited corneal condition

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease

The authors said their results provide strong support that cultivated autologous limbal epithelial cell transplantation is safe and feasible

Researchers indicated that paediatric patients with Leber congenital amaurosis experienced improvements in vision

The company shared 5-year results for lenadogene nolparvovec (Lumevoq), administered unilaterally and bilaterally to patients with Leber Hereditary Optic Neuropathy

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON

Our top 10 print stories highlight the core content concepts we explored this year

Ocular clues to a neurological conditions help clinicians understand neuromyelitis optica spectrum disorder (NMOSD)

Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration